About Acomplia (rimonabant) and clinical trials
Clinical trials are undertaken to demonstrate both the effectiveness and the safety of a drug for human consumption. Human clinical trials will only occur after substantial testing in pre clinical studies has demonstrated the likely effectiveness and safety of the medication to be tested. This final clinical trial will help to determine the most effective dosage and administration regimens, and will help to identify any toxicity in the drug. This human clinical trials stage will also allow for the documentation and categorization of side effects and other adverse reactions to the medication.
The drug Acomplia (rimonabant) was tested in three phases
Phase 1, was used to document and asses the general safety of the drug. Researchers measured the metabolic evolvement of the drug within the body and observed data pertaining to tolerance reactions and any adverse reactions or undesirable side effects.
Phase 2, was used to determine the best dosage regimen and the general effectiveness of rimonabanmt.
Phase 3, Was used to evaluate the efficacy of the medication as regards to weight loss assistance, obesity control and weight maintenance. The drug was evaluated on how well it allowed to people to maintain any weight loss that occurred through the drug’s usage, and the drug’s performance was measured against selected risk factors to obesity.
These trials will continue throughout the lifespan of a drug, and are not stopped after the drug achieves regulatory approval for sale.